Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues

Hybridoma

Volumn 25, Issue 5, 2006, Pages 264-270

  Zhou, Bingsen ^a   Phan, Vu ^a   Liu, Xiyong ^a   Juhasz, Agnes ^a   Chu, Peiguo G ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HRRM2; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ASTROCYTOMA; BREAST CANCER; CANCER; COLON CANCER; CONTROLLED STUDY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBUNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LUNG CANCER; MESOTHELIOMA; MOUSE; MYELOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PURIFICATION; SPLEEN CELL; STOMACH CANCER; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; HYBRIDOMA; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; OROPHARYNX TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; HUMANS; HYBRIDOMAS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOPLASMS; OROPHARYNGEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASES;

EID: 33947239839     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2006.25.264     Document Type: Article

References (17)

1. Shao J, Zhou B, Zhu L, Bilio AJ, Su L, Yuan YC, Ren S, Lien EJ, Shih J, Yen Y: Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochem Pharmacol 2005;69: 627-634.
2. Xue L, Zhou B, Liu X, Qiu W, Jin Z, and Yen Y: Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 2003;63:980-986.
3. Zhou B and Yen Y: Characterization of the human ribonucleotide reductase M2 subunit gene: Genomic structure and promoter analyses. Cytogenet Cell Genet 2001;95:52-59.
4. Zhou B, Mo X, Liu X, Qiu W, and Yen Y: Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet 2001;95:34-42.
5. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, and Thelander L: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in response to DNA damage and in proliferating cells. J Biol Chem 2001;276:40647-40651.
6. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y: A Ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-49.
7. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F, and Yen Y: The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003;63:6583-6594.
8. 2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998;16:43-49.
9. Liu X, Zhou B, Xue L, Qiu W, Shih J, Zheng S, and Yen Y: Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochem Pharmacol 2004;67:1499-1511.
10. Zhou BS, Hsu NY, Pan BC, Doroshow JH, and Yen Y: Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 1995;55:1328-1333.
11. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, and Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004;64:3761-3766.
12. Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, Takao S, and Aikou T: The predictive value of p53, p53R2, p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 2005;92:1-6.
13. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, and Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Can Res 2004;10:1318-1325.
14. Shao J, Zhou B, Zhu L, Qiu W, Yuan YC, Xi B, and Yen Y: In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 2004;64:1-6.
15. Kohler G and Milstein C: Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976;6:511-519.
16. Monoclonal Antibody Production: A Report of the Committee on Methods of Producing Monoclonal Antibodies Institute for Laboratory Animal Research, National Research Council. National Academy Press, Washington, D.C. 1999.
17. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilezynski S, Lenz HJ, Gandara D, Albain KS, and Longmate J, Doroshow JH: Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR versus relative quantification reverse transcription-PCR utilizing DNA sequence analysis of PCR products. J Clin Lab Analysis 2003;17:184-194.